ILC Therapeutics is an early-stage biotechnology company focused on modulating the Innate Immune System.
ILC Therapeutics has raised $3.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2024.
ILC Therapeutics's investors include Scottish Enterprise, Medical Incubator Japan, EOS Technology Investment Syndicate, Robert Kopple.
ILC Therapeutics is headquartered in Newhouse, United Kingdom.
ILC Therapeutics is an early-stage biotechnology company focused on modulating the Innate Immune System.
ILC Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ILC Therapeutics — Funding & Investors." VCBacked, September 11, 2024, https://www.vcbacked.co/company/ilc-therapeutics. Accessed August 15, 2026.
VCBacked. (2024). ILC Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/ilc-therapeutics
{{cite web |title=ILC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ilc-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated